Latest Pharmaceuticals News

Page 30 of 73
Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.
Ada Torres
Ada Torres
12 Nov 2025
Savana Asset Management’s new white paper confirms its algorithmic valuation model can systematically exploit market inefficiencies, highlighted by Canadian Solar’s recent 120% rally and a potential $12 trillion US capex surge.
Claire Turing
Claire Turing
11 Nov 2025
Cann Group Limited has finalized a $15.3 million settlement with National Australia Bank, releasing all security and closing loan facilities as part of a broader debt restructuring. The company is advancing a $9 million new loan and a $9 million capital raise, including a share purchase plan closing November 17.
Ada Torres
Ada Torres
11 Nov 2025
Mayne Pharma has received notice of Cosette Pharmaceuticals' intention to appeal a court ruling in their acquisition dispute, potentially delaying the proposed takeover. The legal saga continues as key approvals and hearings loom.
Victor Sage
Victor Sage
10 Nov 2025
Invex Therapeutics has appointed two new non-executive directors and joint company secretaries, signaling a refreshed governance structure alongside a change of company address.
Ada Torres
Ada Torres
10 Nov 2025
Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.
Ada Torres
Ada Torres
10 Nov 2025
Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.
Ada Torres
Ada Torres
7 Nov 2025
Epsilon Healthcare has commenced operations of its new pharmacy division and extended a key loan facility, signaling a strategic pivot towards integrated healthcare and financial stability after recent restructuring.
Ada Torres
Ada Torres
7 Nov 2025
Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.
Ada Torres
Ada Torres
7 Nov 2025
Neuren Pharmaceuticals reported a milestone quarter with DAYBUE net sales reaching US$101.1 million, driving a 24% jump in royalty income. The expanding patient base and community physician uptake signal strong growth ahead.
Victor Sage
Victor Sage
6 Nov 2025
Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.
Ada Torres
Ada Torres
5 Nov 2025
Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.
Ada Torres
Ada Torres
5 Nov 2025